Question · asked by 1 review
Potassium paraaminobenzoate vs placebo: Quality of life
- Population
- men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during erection: 39 (37%) patients)
- Intervention
- Potassium paraaminobenzoate
- Comparison
- placebo
- Outcome
- Quality of life
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Potassium paraaminobenzoate vs placebo Quality of life · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques… The review found no eligible studies for this question. Non‐surgical therapies for Peyronie's disease (2023) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.